Not yet recruitingPhase 1NCT07430202
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Studying Fibrolamellar hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Marina Baretti, MDSKCCC • Johns Hopkins Medical Institution
- Intervention
- DNAJB1-PRKACA Peptide Vaccine(drug)
- Enrollment
- 27 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2026 – 2030
Study locations (1)
- Johns Hopkins SKCCC, Baltimore, Maryland, United States
Collaborators
Dracen Pharmaceuticals, Inc. · Cancer Research Institute, New York City · Fibrolamellar Cancer Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07430202 on ClinicalTrials.govOther trials for Fibrolamellar hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06789198Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACAUniversity Hospital Tuebingen
- RECRUITINGPHASE1, PHASE2NCT06620302Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar CarcinomaChildren's Oncology Group
- RECRUITINGPHASE1, PHASE2NCT06027086DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGPHASE1NCT05937295FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint InhibitionUniversity Hospital Tuebingen
- RECRUITINGPHASE1, PHASE2NCT05468359Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT04380545Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT04134559Checkpoint Inhibition In Pediatric Hepatocellular CarcinomaAllison O'Neill, MD